2014最新-晚期NSCLC优化治疗选择探讨.pptVIP

吉非替尼组的中位无进展生存期达到5.4个月，长于多西他赛的3.9个月，绝对值延长1.5个月 * 在亚裔腺癌腺癌患者中，EGFR突变率为48%这一比例远高于白种人的？这也解释了为什么TRUST和INTEREST研究中，为何亚裔和中国患者的疗效好于全组，另一半的患者是EGFR野生型。 PFS was significantly longer with Tarceva vs gefitinib, in patients with adenocarcinoma histology who were light ex-smokers (IPASS group) median PFS 7.2 vs 5.1 months, respectively; p0.001. Due to enrichment by clinical selection, the IPASS group is likely to contain more patients with EGFR activating mutations, compared with the non-IPASS group. * 腺癌亚组分析中我们可以看到，特罗凯组的DCR达到72.8%，而吉非替尼组仅64.3%。均有统计学差异 US tracking Q4, 2012 国内EGFR检测率仅是美国的1/4 Source: Ipsos Ch